P
Patrick Wanningen
Researcher at Janssen Pharmaceutica
Publications - 2
Citations - 453
Patrick Wanningen is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Antigen & Chemistry. The author has an hindex of 1, co-authored 1 publications receiving 373 citations.
Papers
More filters
Journal ArticleDOI
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.
Antonietta Impagliazzo,Fin Milder,Harmjan Kuipers,Michelle Wagner,Xueyong Zhu,Ryan M. B. Hoffman,Ruud van Meersbergen,Jeroen Huizingh,Patrick Wanningen,Johan Verspuij,Martijn de Man,Zhaoqing Ding,Adrian Apetri,Başak Kükrer,Eveline Sneekes-Vriese,Danuta Tomkiewicz,Nick S. Laursen,Peter Lee,Anna Zakrzewska,Liesbeth Dekking,Jeroen Tolboom,Lisanne Tettero,Sander van Meerten,Wenli Yu,Wouter Koudstaal,Jaap Goudsmit,Andrew B. Ward,Wim Meijberg,Ian A. Wilson,Katarina Radosevic +29 more
TL;DR: The results represent a proof of concept for the design of HA stem mimics that elicit bnAbs against influenza A group 1 viruses and completely protects mice in lethal heterologous and heterosubtypic challenge models, and reduces fever after sublethal challenge in cynomolgus monkeys.
Journal ArticleDOI
Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
Dorothée Bardiot,Laura Vangeel,Mohamed Koukni,Philippe Arzel,Marleen Zwaagstra,Heyrhyoung Lyoo,Patrick Wanningen,S. Ahmad,Linlin Zhang,Xin-Kuan Sun,Adrien Delpal,Cécilia Eydoux,Jean-Claude Guillemot,Eveline Lescrinier,Hugo Klaassen,Pieter Leyssen,Dirk Jochmans,Karolien Castermans,Rolf Hilgenfeld,Colin Robinson,Etienne Decroly,Bruno Canard,Eric J. Snijder,Martijn J. van Hemert,Frank J. M. van Kuppeveld,Patrick Chaltin,Johan Neyts,Steven De Jonghe,Arnaud Marchand +28 more
TL;DR: A high-throughput screening of a 160 K compound library against SARS-CoV-2 yielded a 1-heteroaryl-2-alkoxyphenyl analog as a promising hit, and a systematic structure–activity relationship (SAR) study demonstrated that a 3- or 4-pyridyl moiety on the oxadiazole moiety is optimal, whereas the oxADiazole can be replaced by various other heteroaromatic cycles.